Literature DB >> 8121547

Reversal of subarachnoid hemorrhage-induced vasoconstriction with an endothelin receptor antagonist.

P L Foley1, H H Caner, N F Kassell, K S Lee.   

Abstract

Increased concentrations of the vasoconstrictor endothelin have recently been demonstrated in the cerebrospinal fluid after subarachnoid hemorrhage (SAH). This observation is consistent with the hypothesis that SAH-induced vasopasm is mediated in part by enhanced constriction due to endothelin. To investigate the issue, an endothelin receptor antagonist (ETant), cyclo(D-Asp-L-Pro-D-Val-L-Leu-D-Trp), was tested for its ability to reverse vasoconstriction after SAH. A transclival surgical approach to the basilar artery in rabbits was used, and the arterial diameter was measured continuously by videomicroscopy. Rabbits were divided randomly into six groups: 1) normal rabbits treated with 40 nmol/L ETant only; 2) normal rabbits treated with 50 mmol/L KCl, then 50 mmol/L KCl + 40 nmol/L ETant; 3) normal rabbits treated with 20 nmol/L endothelin-1 (ET-1), then 20 nmol/L ET-1 + 40 nmol/L ETant; 4) rabbits treated with 20 nmol/L ET-1 only; 5) rabbits subjected to SAH and treated with 40 nmol/L ETant; and 6) rabbits subjected to SAH and treated with artificial cerebrospinal fluid only. In normal (non-SAH) rabbits, ETant: 1) had little or no effect on resting tone; 2) did not reverse potassium-induced constrictions; and 3) substantially reversed endothelin-induced constrictions. The diameter of normal rabbit basilar arteries was 832.1 +/- 20.0 microns (mean +/- standard error). After SAH (double hemorrhage model), the mean diameter was 517.4 +/- 18.3 microns. The addition of ETant reversed this SAH-induced constriction by 70.7%.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8121547

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  5 in total

Review 1.  The single and double blood injection rabbit subarachnoid hemorrhage model.

Authors:  Yuichiro Kikkawa; Ryota Kurogi; Tomio Sasaki
Journal:  Transl Stroke Res       Date:  2014-11-08       Impact factor: 6.829

2.  Influence of different degrees of liver impairment on the pharmacokinetics of clazosentan.

Authors:  Shirin Bruderer; Victor Detishin; Nahum Tsvitbaum; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2011-01       Impact factor: 4.335

Review 3.  Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology.

Authors:  Fan Fan; Ying Ge; Wenshan Lv; Matthew R Elliott; Yoshikazu Muroya; Takashi Hirata; George W Booz; Richard J Roman
Journal:  Front Biosci (Landmark Ed)       Date:  2016-06-01

Review 4.  Effect of endothelin receptor antagonists on clinically relevant outcomes after experimental subarachnoid hemorrhage: a systematic review and meta-analysis.

Authors:  Kamil G Laban; Mervyn D I Vergouwen; Rick M Dijkhuizen; Emily S Sena; Malcolm R Macleod; Gabriel J E Rinkel; H Bart van der Worp
Journal:  J Cereb Blood Flow Metab       Date:  2015-05-06       Impact factor: 6.200

5.  Suppression of the Rho/Rho-kinase pathway and prevention of cerebral vasospasm by combination treatment with statin and fasudil after subarachnoid hemorrhage in rabbit.

Authors:  Masato Naraoka; Akira Munakata; Naoya Matsuda; Norihito Shimamura; Hiroki Ohkuma
Journal:  Transl Stroke Res       Date:  2013-01-29       Impact factor: 6.829

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.